Rosiglitazone attenuates renal injury caused by hyperlipidemic pancreatitis
Hyperlipidemic pancreatitis (HP) is a serious inflammatory disease with very high mortality and multiple organ injuries including renal injury. Rosiglitazone (Ros), an agonist of peroxisome proliferator activated receptor-γ (PPAR-γ), was reported to show a protective role against pancreatitis. Howev...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical and experimental pathology 2015-01, Vol.8 (5), p.4332-4343 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4343 |
|---|---|
| container_issue | 5 |
| container_start_page | 4332 |
| container_title | International journal of clinical and experimental pathology |
| container_volume | 8 |
| creator | Wang, Rui Yan, Zhaopeng Wu, Xingmao Ji, Kaiqiang Wang, Haiyuan Zang, Bin |
| description | Hyperlipidemic pancreatitis (HP) is a serious inflammatory disease with very high mortality and multiple organ injuries including renal injury. Rosiglitazone (Ros), an agonist of peroxisome proliferator activated receptor-γ (PPAR-γ), was reported to show a protective role against pancreatitis. However, whether Ros has an effect on renal injury caused by HP is not yet clear. In the present study, the function of Ros was explored using ELISA, RT-PCR, western blot, PAS staining and immunohistochemistry. Results of this study showed that Ros could inhibit the activation of NF-κB and MAPK P38 signaling pathways, relieve inflammatory response and inhibit cell apoptosis, thus attenuating renal injury caused by HP. This study suggested that Ros might be a promising drug for the treatment of renal injury caused by HP and also laid theoretical foundation for the development of renal injury treatment. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4502997</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1697757492</sourcerecordid><originalsourceid>FETCH-LOGICAL-p266t-12b089d38bd39eca001bb7fd58484514b0412c428fbbeb2f152c59989ea469593</originalsourceid><addsrcrecordid>eNpVkM1KxDAYRYsgzjj6CpKlm0KSJmmzEWTwDwVBdB2S9OtMhjStSSrUp3fAUXR1F_dyDtyjYklkJUoqKF8UpyntMBaEMnxSLKggkhDKl8Xjy5DcxrusP4cASOcMYdIZEooQtEcu7KY4I6unBC0yM9rOI0TvRtdC7ywadbARdHbZpbPiuNM-wfkhV8Xb7c3r-r58er57WF8_lSMVIpeEGtzItmpMW0mwGmNiTN21vGEN44QZzAi1jDadMWBoRzi1XMpGgmZCclmtiqtv7jiZHloLIUft1Rhdr-OsBu3U_ya4rdoMH4pxTKWs94DLAyAO7xOkrHqXLHivAwxTUkTIuuY1k3Q_vfjr-pX8PFh9AXarblM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1697757492</pqid></control><display><type>article</type><title>Rosiglitazone attenuates renal injury caused by hyperlipidemic pancreatitis</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Wang, Rui ; Yan, Zhaopeng ; Wu, Xingmao ; Ji, Kaiqiang ; Wang, Haiyuan ; Zang, Bin</creator><creatorcontrib>Wang, Rui ; Yan, Zhaopeng ; Wu, Xingmao ; Ji, Kaiqiang ; Wang, Haiyuan ; Zang, Bin</creatorcontrib><description>Hyperlipidemic pancreatitis (HP) is a serious inflammatory disease with very high mortality and multiple organ injuries including renal injury. Rosiglitazone (Ros), an agonist of peroxisome proliferator activated receptor-γ (PPAR-γ), was reported to show a protective role against pancreatitis. However, whether Ros has an effect on renal injury caused by HP is not yet clear. In the present study, the function of Ros was explored using ELISA, RT-PCR, western blot, PAS staining and immunohistochemistry. Results of this study showed that Ros could inhibit the activation of NF-κB and MAPK P38 signaling pathways, relieve inflammatory response and inhibit cell apoptosis, thus attenuating renal injury caused by HP. This study suggested that Ros might be a promising drug for the treatment of renal injury caused by HP and also laid theoretical foundation for the development of renal injury treatment.</description><identifier>EISSN: 1936-2625</identifier><identifier>PMID: 26191125</identifier><language>eng</language><publisher>United States: e-Century Publishing Corporation</publisher><subject>Acute Kidney Injury - etiology ; Acute Kidney Injury - prevention & control ; Animals ; Blotting, Western ; Disease Models, Animal ; Enzyme-Linked Immunosorbent Assay ; Hyperlipidemias - complications ; Hypoglycemic Agents - pharmacology ; Immunohistochemistry ; In Situ Nick-End Labeling ; Male ; Original ; Pancreatitis - complications ; Rats ; Rats, Sprague-Dawley ; Real-Time Polymerase Chain Reaction ; Reverse Transcriptase Polymerase Chain Reaction ; Thiazolidinediones - pharmacology</subject><ispartof>International journal of clinical and experimental pathology, 2015-01, Vol.8 (5), p.4332-4343</ispartof><rights>IJCEP Copyright © 2015 2015</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4502997/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4502997/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,724,777,781,882,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26191125$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Rui</creatorcontrib><creatorcontrib>Yan, Zhaopeng</creatorcontrib><creatorcontrib>Wu, Xingmao</creatorcontrib><creatorcontrib>Ji, Kaiqiang</creatorcontrib><creatorcontrib>Wang, Haiyuan</creatorcontrib><creatorcontrib>Zang, Bin</creatorcontrib><title>Rosiglitazone attenuates renal injury caused by hyperlipidemic pancreatitis</title><title>International journal of clinical and experimental pathology</title><addtitle>Int J Clin Exp Pathol</addtitle><description>Hyperlipidemic pancreatitis (HP) is a serious inflammatory disease with very high mortality and multiple organ injuries including renal injury. Rosiglitazone (Ros), an agonist of peroxisome proliferator activated receptor-γ (PPAR-γ), was reported to show a protective role against pancreatitis. However, whether Ros has an effect on renal injury caused by HP is not yet clear. In the present study, the function of Ros was explored using ELISA, RT-PCR, western blot, PAS staining and immunohistochemistry. Results of this study showed that Ros could inhibit the activation of NF-κB and MAPK P38 signaling pathways, relieve inflammatory response and inhibit cell apoptosis, thus attenuating renal injury caused by HP. This study suggested that Ros might be a promising drug for the treatment of renal injury caused by HP and also laid theoretical foundation for the development of renal injury treatment.</description><subject>Acute Kidney Injury - etiology</subject><subject>Acute Kidney Injury - prevention & control</subject><subject>Animals</subject><subject>Blotting, Western</subject><subject>Disease Models, Animal</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Hyperlipidemias - complications</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Immunohistochemistry</subject><subject>In Situ Nick-End Labeling</subject><subject>Male</subject><subject>Original</subject><subject>Pancreatitis - complications</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Real-Time Polymerase Chain Reaction</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>Thiazolidinediones - pharmacology</subject><issn>1936-2625</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkM1KxDAYRYsgzjj6CpKlm0KSJmmzEWTwDwVBdB2S9OtMhjStSSrUp3fAUXR1F_dyDtyjYklkJUoqKF8UpyntMBaEMnxSLKggkhDKl8Xjy5DcxrusP4cASOcMYdIZEooQtEcu7KY4I6unBC0yM9rOI0TvRtdC7ywadbARdHbZpbPiuNM-wfkhV8Xb7c3r-r58er57WF8_lSMVIpeEGtzItmpMW0mwGmNiTN21vGEN44QZzAi1jDadMWBoRzi1XMpGgmZCclmtiqtv7jiZHloLIUft1Rhdr-OsBu3U_ya4rdoMH4pxTKWs94DLAyAO7xOkrHqXLHivAwxTUkTIuuY1k3Q_vfjr-pX8PFh9AXarblM</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Wang, Rui</creator><creator>Yan, Zhaopeng</creator><creator>Wu, Xingmao</creator><creator>Ji, Kaiqiang</creator><creator>Wang, Haiyuan</creator><creator>Zang, Bin</creator><general>e-Century Publishing Corporation</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150101</creationdate><title>Rosiglitazone attenuates renal injury caused by hyperlipidemic pancreatitis</title><author>Wang, Rui ; Yan, Zhaopeng ; Wu, Xingmao ; Ji, Kaiqiang ; Wang, Haiyuan ; Zang, Bin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p266t-12b089d38bd39eca001bb7fd58484514b0412c428fbbeb2f152c59989ea469593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Acute Kidney Injury - etiology</topic><topic>Acute Kidney Injury - prevention & control</topic><topic>Animals</topic><topic>Blotting, Western</topic><topic>Disease Models, Animal</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Hyperlipidemias - complications</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Immunohistochemistry</topic><topic>In Situ Nick-End Labeling</topic><topic>Male</topic><topic>Original</topic><topic>Pancreatitis - complications</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Real-Time Polymerase Chain Reaction</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>Thiazolidinediones - pharmacology</topic><toplevel>online_resources</toplevel><creatorcontrib>Wang, Rui</creatorcontrib><creatorcontrib>Yan, Zhaopeng</creatorcontrib><creatorcontrib>Wu, Xingmao</creatorcontrib><creatorcontrib>Ji, Kaiqiang</creatorcontrib><creatorcontrib>Wang, Haiyuan</creatorcontrib><creatorcontrib>Zang, Bin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of clinical and experimental pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Rui</au><au>Yan, Zhaopeng</au><au>Wu, Xingmao</au><au>Ji, Kaiqiang</au><au>Wang, Haiyuan</au><au>Zang, Bin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rosiglitazone attenuates renal injury caused by hyperlipidemic pancreatitis</atitle><jtitle>International journal of clinical and experimental pathology</jtitle><addtitle>Int J Clin Exp Pathol</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>8</volume><issue>5</issue><spage>4332</spage><epage>4343</epage><pages>4332-4343</pages><eissn>1936-2625</eissn><abstract>Hyperlipidemic pancreatitis (HP) is a serious inflammatory disease with very high mortality and multiple organ injuries including renal injury. Rosiglitazone (Ros), an agonist of peroxisome proliferator activated receptor-γ (PPAR-γ), was reported to show a protective role against pancreatitis. However, whether Ros has an effect on renal injury caused by HP is not yet clear. In the present study, the function of Ros was explored using ELISA, RT-PCR, western blot, PAS staining and immunohistochemistry. Results of this study showed that Ros could inhibit the activation of NF-κB and MAPK P38 signaling pathways, relieve inflammatory response and inhibit cell apoptosis, thus attenuating renal injury caused by HP. This study suggested that Ros might be a promising drug for the treatment of renal injury caused by HP and also laid theoretical foundation for the development of renal injury treatment.</abstract><cop>United States</cop><pub>e-Century Publishing Corporation</pub><pmid>26191125</pmid><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1936-2625 |
| ispartof | International journal of clinical and experimental pathology, 2015-01, Vol.8 (5), p.4332-4343 |
| issn | 1936-2625 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4502997 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Acute Kidney Injury - etiology Acute Kidney Injury - prevention & control Animals Blotting, Western Disease Models, Animal Enzyme-Linked Immunosorbent Assay Hyperlipidemias - complications Hypoglycemic Agents - pharmacology Immunohistochemistry In Situ Nick-End Labeling Male Original Pancreatitis - complications Rats Rats, Sprague-Dawley Real-Time Polymerase Chain Reaction Reverse Transcriptase Polymerase Chain Reaction Thiazolidinediones - pharmacology |
| title | Rosiglitazone attenuates renal injury caused by hyperlipidemic pancreatitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T20%3A26%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rosiglitazone%20attenuates%20renal%20injury%20caused%20by%20hyperlipidemic%20pancreatitis&rft.jtitle=International%20journal%20of%20clinical%20and%20experimental%20pathology&rft.au=Wang,%20Rui&rft.date=2015-01-01&rft.volume=8&rft.issue=5&rft.spage=4332&rft.epage=4343&rft.pages=4332-4343&rft.eissn=1936-2625&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1697757492%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1697757492&rft_id=info:pmid/26191125&rfr_iscdi=true |